Form D · Biotechnology

Atsena Therapeutics, Inc.

Durham, NC · CIK 0001811468

Offering snapshot reported Apr 11, 2025 · SEC filing

Reported sold
$90M
Offering amount: $150M
Investors reported
14
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 27, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 11, 2025Initial$89,999,975No comparison14SEC filing
Oct 2, 2023Initial$24,474,387No comparison10SEC filing
Dec 23, 2020Initial$27,499,973No comparison11SEC filing
May 8, 2020Initial$4,074,989No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$4.78M
Finders' fees
$0
Form D file number
021-543461
see item 12. Wedbush Securities Inc.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Wedbush Securities Inc.877

Source: Form D, filed Apr 11, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Shannon Boye Director
Sanford Boye Executive
Chris Carpenter Director
Michael Dial Director
Jacqueline Grant Director
James Healy Director
Christina Isacson Director
Elizabeth Leiderman Executive
Norbert Riedel Director
Patrick Ritschel Director, Executive
Jennifer Wellman Director
Benjamin Yerxa Director
Joe Zakrzewski Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
8 Davis Drive, Suite 300
Durham, NC, 27709